- Home
- APLM vs JZXN Comparison
APLM vs JZXN Comparison
Compare APLM & JZXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- JZXN
- Stock Information
- Founded
- APLM 2016
- JZXN 2019
- Country
- APLM United States
- JZXN China
- Employees
- APLM N/A
- JZXN N/A
- Industry
- APLM Blank Checks
- JZXN Retail-Auto Dealers and Gas Stations
- Sector
- APLM Finance
- JZXN Consumer Discretionary
- Exchange
- APLM Nasdaq
- JZXN Nasdaq
- Market Cap
- APLM 6.9M
- JZXN N/A
- IPO Year
- APLM N/A
- JZXN 2021
- Fundamental
- Price
- APLM $6.56
- JZXN $1.05
- Analyst Decision
- APLM
- JZXN
- Analyst Count
- APLM 0
- JZXN 0
- Target Price
- APLM N/A
- JZXN N/A
- AVG Volume (30 Days)
- APLM 6.5K
- JZXN 482.9K
- Earning Date
- APLM 08-13-2025
- JZXN 03-03-2025
- Dividend Yield
- APLM N/A
- JZXN N/A
- EPS Growth
- APLM N/A
- JZXN N/A
- EPS
- APLM N/A
- JZXN N/A
- Revenue
- APLM $198,000.00
- JZXN $1,400,139.00
- Revenue This Year
- APLM $415.15
- JZXN N/A
- Revenue Next Year
- APLM N/A
- JZXN N/A
- P/E Ratio
- APLM N/A
- JZXN N/A
- Revenue Growth
- APLM N/A
- JZXN N/A
- 52 Week Low
- APLM $4.47
- JZXN $0.84
- 52 Week High
- APLM $35.98
- JZXN $7.82
- Technical
- Relative Strength Index (RSI)
- APLM 53.03
- JZXN 30.65
- Support Level
- APLM $6.21
- JZXN $0.85
- Resistance Level
- APLM $6.80
- JZXN $1.70
- Average True Range (ATR)
- APLM 0.50
- JZXN 0.34
- MACD
- APLM 0.02
- JZXN -0.04
- Stochastic Oscillator
- APLM 77.22
- JZXN 8.54
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.